Therapeutic high-dose vitamin D for vitamin D-deficient severe COVID-19 disease: randomized, double-blind, placebo-controlled study (SHADE-S)
Journal of Public Health · 2024
DOI: 10.1093/pubmed/fdae007 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Public Health, 2024. Verfasst von Ajay Singh und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesia and Intensive Care, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: COVID-19, Vitamin D Deficiency, SARS-CoV-2, Cholecalciferol. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background efficacy of therapeutic cholecalciferol supplementation for severe COVID-19 is sparingly studied. Objective effect of single high-dose cholecalciferol supplementation on sequential organ failure assessment (SOFA) score in moderate-to-severe COVID-19. Methods participants with moderate to severe COVID-19 with PaO2/FiO2 ratio < 200 were randomized to 0.6 million IU cholecalciferol oral (intervention) or placebo. Outcomes primary outcome was change in Day 7 SOFA score and pre-specified secondary outcomes were SOFA and 28-day all-cause mortality. Results in all, 90 patients (45 each group) were included for intention-to-treat analysis. 25(OH)D3 levels were 12 (10–16) and 13 (12–18) ng/ml (P = 0.06) at baseline; and 60 (55–65) ng/ml and 4 (1–7) ng/ml by Day 7 in vitamin D and placebo groups, respectively. The SOFA score on Day 7 was better in the vitamin D group [3 (95% CI, 2–5) versus 5 (95% CI, 3–7), P = 0.01, intergroup difference − 2 (95% CI, −4 to −0.01); r = 0.4]. A lower all-cause 28-day mortality [24% compared to 44% (P = 0.046)] was observed with vitamin D. Conclusions single high-dose oral cholecalciferol supplementation on ICU admission can improve SOFA score at Day 7 and reduce in-hospital mortality in vitamin D-deficient COVID-19. ClinicalTrials.gov id: NCT04952857 registered dated 7 July 2021. What is already known on this topic—vitamin D has immunomodulatory role. Observational and isolated intervention studies show some benefit in COVID-19. Targeted therapeutic vitamin D supplementation improve outcomes in severe COVID-19 is not studied in RCTs. What this study adds—high-dose vitamin D supplementation (0.6 Million IU) to increase 25(OH)D > 50 ng/ml is safe and reduces sequential organ failure assessment score, in-hospital mortality in moderate to severe COVID-19. How this study might affect research, practice or policy—vitamin D supplementation in vitamin D-deficient patients with severe COVID-19 is useful may be practiced.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anaesthesia and Intensive Care, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Community Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
ORCID-Profile: Ajay Singh, Ashu Rastogi
Zitieren
APA
Singh, A., Rastogi, A., Puri, G. D., Ganesh, V., Naik, N. B., Kajal, K., Kahlon, S., Soni, S. L., Kaloria, N., Saini, K., Hazarika, A., Mahajan, V., Singla, K., Bhadada, S., & Soni, V. (2024). Therapeutic high-dose vitamin D for vitamin D-deficient severe COVID-19 disease: randomized, double-blind, placebo-controlled study (SHADE-S). Journal of Public Health. https://doi.org/10.1093/pubmed/fdae007
Vancouver
Singh A, Rastogi A, Puri GD, Ganesh V, Naik NB, Kajal K, et al. Therapeutic high-dose vitamin D for vitamin D-deficient severe COVID-19 disease: randomized, double-blind, placebo-controlled study (SHADE-S). Journal of Public Health. 2024. doi:10.1093/pubmed/fdae007
BibTeX
@article{Singh2024,
author = {Singh, Ajay and Rastogi, Ashu and Puri, Goverdhan Dutt and Ganesh, Venkata and Naik, Naveen Bal and Kajal, Kamal and Kahlon, Shubhkarman and Soni, Shiv Lal and Kaloria, Narender and Saini, Kulbhushan and Hazarika, Amarjyoti and Mahajan, Varun and Singla, Karan and Bhadada, Sanjay and Soni, Vaishali},
title = {Therapeutic high-dose vitamin D for vitamin D-deficient severe COVID-19 disease: randomized, double-blind, placebo-controlled study (SHADE-S)},
journal = {Journal of Public Health},
year = {2024},
doi = {10.1093/pubmed/fdae007}
}
EUVIMED